| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1083412081 |
| P356 | DOI | 10.1186/S13045-016-0374-Y |
| P932 | PMC publication ID | 5288948 |
| P698 | PubMed publication ID | 28153029 |
| P2093 | author name string | Shenhong Wu | |
| Chunhui Fang | |||
| Kevin Zarrabi | |||
| P2860 | cites work | Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Q21198871 |
| Immunotherapy for advanced renal cell cancer | Q24246777 | ||
| mTOR inhibitors in advanced renal cell carcinoma | Q24612127 | ||
| Axitinib for the management of metastatic renal cell carcinoma | Q24613720 | ||
| Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Q26745516 | ||
| Renal cell carcinoma: links and risks | Q26750417 | ||
| Sequence of treatment in locally advanced and metastatic renal cell carcinoma | Q26773653 | ||
| Metastatic Renal Cell Cancer: Summary from ASCO 2015 | Q26796392 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial | Q33750154 | ||
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 | ||
| Renal cancer. | Q50941188 | ||
| [Combination of Targeted Therapy and Immunotherapy for Cancer]. | Q52909682 | ||
| [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic r | Q53352740 | ||
| Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States. | Q54192985 | ||
| Renal-cell carcinoma--molecular pathways and therapies. | Q55042930 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe | Q73471160 | ||
| Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma | Q87001514 | ||
| Recent developments in second and third line therapy of metastatic renal cell carcinoma | Q87508846 | ||
| Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. | Q38175454 | ||
| Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity | Q38214357 | ||
| Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma | Q38367115 | ||
| Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial | Q38391922 | ||
| A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer | Q38574759 | ||
| Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives | Q38721253 | ||
| Emerging therapeutics in refractory renal cell carcinoma | Q38816892 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma | Q38851881 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. | Q38917870 | ||
| Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy | Q38975732 | ||
| Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Ste | Q40981962 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Treatment Beyond Progression: Is It Moving from Belief to Evidence? | Q42995231 | ||
| Kinase inhibition with BAY 43-9006 in renal cell carcinoma | Q45077916 | ||
| Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma | Q45264009 | ||
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 | ||
| E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition | Q46944486 | ||
| Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial | Q33922560 | ||
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 | ||
| Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature | Q34034222 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Q34322740 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Sunitinib in patients with metastatic renal cell carcinoma | Q34568166 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Chemotherapy in metastatic renal cell carcinoma today? A systematic review | Q34650032 | ||
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 | ||
| The prospects of pazopanib in advanced renal cell carcinoma | Q34656393 | ||
| Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. | Q34658095 | ||
| Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study | Q34660897 | ||
| Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 | ||
| Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo | Q35235365 | ||
| EAU guidelines on renal cell carcinoma: 2014 update. | Q35548292 | ||
| Will mTOR inhibitors make it as cancer drugs? | Q35604822 | ||
| A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours | Q35949539 | ||
| Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma | Q36043473 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease | Q36696610 | ||
| Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy | Q36718954 | ||
| Opportunities and obstacles to combination targeted therapy in renal cell cancer. | Q36718987 | ||
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 | ||
| mTOR signalling in human cancer | Q36919646 | ||
| Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors | Q37069569 | ||
| Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) | Q37220273 | ||
| Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. | Q37350230 | ||
| Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma | Q37409862 | ||
| A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). | Q37470131 | ||
| Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway | Q38078784 | ||
| Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial | Q38160956 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| angiogenesis inhibitor | Q574834 | ||
| renal cell carcinoma | Q1164529 | ||
| kidney neoplasm | Q13641482 | ||
| metastatic renal cell carcinoma | Q19000948 | ||
| investigational therapy | Q73510198 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 38 | |
| P577 | publication date | 2017-02-02 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy | |
| P478 | volume | 10 |
| Q89849302 | A Case Report with Severe Thrombocytopenia Induced by Axitinib |
| Q38662419 | A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma |
| Q48226648 | A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. |
| Q52611170 | Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. |
| Q57598537 | Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases |
| Q93104008 | Emerging therapeutic agents for genitourinary cancers |
| Q41573990 | Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. |
| Q93208369 | Knockdown of ALPK2 blocks development and progression of renal cell carcinoma |
| Q44631161 | Lingual metastasis as an initial presentation of renal cell carcinoma: a case report |
| Q93017711 | MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions |
| Q47703386 | MicroRNAs in cancer metastasis and angiogenesis |
| Q59793924 | Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity |
| Q47813600 | Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety |
| Q64103672 | Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy |
| Q89393258 | Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies |
| Q92977454 | Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results |
| Q91844057 | Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data |
| Q50078523 | Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. |
Search more.